Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

S100A9 (S100 calcium binding protein A9)

Written2011-02Claus Kerkhoff, Saeid Ghavami
Dept VAC / IMCI, Helmholtz Centre for Infection Research, Inhoffenstr 7, D-38124 Braunschweig, Germany (CK); Department of Physiology, University of Manitoba, Winnipeg, Manitoba, Canada (SG)

(Note : for Links provided by Atlas : click)

Identity

Alias_namesCAGB
CFAG
S100 calcium-binding protein A9 (calgranulin B)
S100 calcium binding protein A9 (calgranulin B)
Alias_symbol (synonym)P14
MIF
NIF
LIAG
MRP14
MAC387
60B8AG
CGLB
Other aliasL1AG
HGNC (Hugo) S100A9
LocusID (NCBI) 6280
Atlas_Id 45569
Location 1q21.3  [Link to chromosome band 1q21]
Location_base_pair Starts at 153357854 and ends at 153361027 bp from pter ( according to hg19-Feb_2009)  [Mapping S100A9.png]
Local_order Distal to PGLYRP4 peptidoglycan recognition protein 4, proximal to S100A12 (S100 calcium binding protein A12).
Fusion genes
(updated 2016)
ANKRD11 (16q24.3) / S100A9 (1q21.3)CCDC12 (3p21.31) / S100A9 (1q21.3)KRT4 (12q13.13) / S100A9 (1q21.3)
MSRA (8p23.1) / S100A9 (1q21.3)R3HDM4 (19p13.3) / S100A9 (1q21.3)RBM18 (9q33.2) / S100A9 (1q21.3)
S100A9 (1q21.3) / KRT4 (12q13.13)S100A9 (1q21.3) / VAT1L (16q23.1)

DNA/RNA

Note S100A9 belongs to the S100/calgranulin family of small non-ubiquitous cytoplasmic Ca2+-binding proteins of EF-hand type. The proteins were referred to "S100" because of their solubility in saturated ammonium sulphate solution. Sixteen of 21 members are localised in a cluster on human chromosome 1q21.
The clustered organization of these S100 genes is conserved during evolution (Ridinger et al., 1998). A comparison between man and mouse has shown that during evolution, the colinearity of the S100 gene cluster has been destroyed by some inversions. However, the colocalization of the myeloid expressed S100 genes such as S100A8, S100A9, and S100A12 is conserved. It has been speculated, that the structural integrity of that part of the locus is necessary for the coordinated expression of these genes (Nacken et al., 2001).
Remarkably, the S100 gene cluster is located in close proximity to a region which has been frequently rearranged in human cancer (Carlsson et al., 2005) and to the epidermal differentiation complex (EDC) (Mischke et al., 1996). EDC is a cluster of genes on chromosome 1q21 encoding proteins that fulfil important functions in terminal differentiation in the human epidermis, including filaggrin, loricrin and others. In addition, linkage analyses have identified a psoriasis susceptibility region, the PSORS4 locus, that is close to the S100 gene cluster (Hardas et al., 1996; Semprini et al., 2002). These data are important indications for the involvement of S100 genes in inflammatory as well as neoplastic disorders. It has been speculated that the rearrangements result in a deregulated expression of S100 genes associated with neoplasia.
Description The S100 gene structure has been structurally conserved during evolution. Similar to most S100 genes S100A9 consists of three exons that are separated by two introns.
Transcription In the S100A9 gene, exon 1 encodes the untranslated region. The protein is encoded by sequences in exon 2 and exon 3, encoding a N-terminal and a C-terminal EF-hand motif, respectively.
The sequence of human S100A9 cDNA has an open reading frame of 352 nucleotides.
S100A9 expression appears to be restricted to a specific stage of myeloid differentiation. The protein is present in circulating neutrophils and monocytes, but not in resting tissue macrophages. In peripheral blood monocytes it is down regulated during maturation to macrophages. Despite a number of distinct regulatory regions are located upstream of the transcription initiation site, the corresponding nuclear factors as well as the underlying molecular mechanisms still remain unclear. Transcription factors such as PU.1 (Henkel et al., 2002), C/EBP-alpha and C/EBP-beta (Kuruto-Niwa et al., 1998) have been shown to drive S100 gene expression within the myeloid lineage.
For example, during differentiation of HL-60 cells into monocyte-like cells two still not identified factors were found to bind to the upstream regions of S100A9 gene; one adjacent to the TATA box and another in the region between -400 and -150 (Kuwayama et al., 1993). Another study revealed a CCAAT/enhancer binding protein (C/EBP)-binding motif located at position -81 upstream of the S100A9 gene. Both C/EBP-alpha and -beta bind to this motif in a myeloid/monocytic differentiation-dependent manner (Kuruto-Niwa et al., 1998). C/EBP was shown to be alone sufficient to drive S100A9 expression in otherwise negative cells. C/EBP up-regulation is antagonized by myb, a transcription factor active in differentiated myeloid/monocytic cells (Klempt et al., 1998). The presence of distinct epithelial and myeloid-specific regulatory regions upstream of the transcription initiation site has been demonstrated by detailed deletion analysis (Klempt et al., 1999). Besides the very specific action of particular upstream DNA elements, the S100A9 gene contains a potent enhancer, which is harbored within positions 153 to 361 of its first intron (Melkonyan et al., 1998). The functional relevance of this enhancer in S100A9 expression is supported by its conservation in human and murine S100A9 genes at almost identical positions.
Promoter analyses revealed a regulatory element within the S100A9 promoter referred to as MRP regulatory element (MRE) that drives the S100A9 gene expression in a cell-specific and differentiation-dependent manner. This regulatory region is located at position -400 to -374 bp, and two distinct nuclear complexes were demonstrated to bind to this region. Interestingly, the formation of the nuclear protein complexes closely correlates with the myeloid-specific expression of the S100A9 gene and, were therefore referred to as MRE-binding complex A (MbcA) and MbcB, respectively. Analysis of one of the two nuclear complexes revealed a heterocomplex consisting of transcriptional intermediary factor 1 beta (TIF1 beta) and a yet unidentified protein with homology to KRAB domain-containing (Kruppel-related) zinc finger proteins (ZFP) (Kerkhoff et al., 2002).
Beside its expression in myeloid cells S100A9 is expressed in epithelia under specific conditions. Its expression is transiently induced in keratinocytes after epidermal injury and UVB irradiation, and the protein is expressed at extremely high levels in psoriatic keratinocytes. Furthermore, its expression is induced by pro-inflammatory cytokines such as TNF alpha and IL1 beta. Recently, a complex of Poly (ADP-ribose) polymerase (PARP-1) and Ku70/Ku80 has been demonstrated to drive the stress response-specific S100 gene expression (Grote et al., 2006). The stress response-induced expression of the S100 proteins points to an important role in skin pathology.
In breast cancer cells S100A9 gene expression is induced by the cytokine oncostatin M (OM) through the STAT3-signaling cascade (Li et al., 2004). This finding is in accordance with another study showing that IL-22 up-regulates the expression of S100A7, S100A8, and S100A9 in keratinocytes. IL-22 has been demonstrated to induce STAT3 activation in keratinocytes (Boniface et al., 2005).
Pseudogene Not known.

Protein

 
  Gene: Box = exon (light blue = 5'UTR, yellow = CDS, red = 3'UTR); Line = intron.
Protein: Upper boxes, alternating colours: exons (coding part only). Lower boxes: protein domains. Green box = not structure; blue box = helix; violett box = calcium-binding domain.
Description The sequence of human S100A9 cDNA has an open reading frame of 352 nucleotides predicting a protein of 114 amino acids and a calculated Mr of 13242 Da.
Beside the full-length form of S100A9 there is a truncated isoform of S100A9 resulting from alternative translation.
The full-length form of S100A9 lacks the first Met, and Thr at position 2 is acetylated leading to a calculated molecular mass of 13154 Da.
The N-truncated isoform starts with Met at position 5. Posttranslational removing of Met at position 5 and consequent acetylation of Ser at position 6 leads to a calculated molecular mass of 12690 Da.
The theoretical isoelectric point of the full length form is 5.7 and for the truncated form is 5.5, respectively.
S100A9 is composed of two helix-loop-helix EF-hand motifs. The C-terminal EF-hand contains a canonical Ca2+-binding loop of 12 amino acids. Conversely, the N-terminal EF-hand contains a Ca2+-binding loop of 14 residues that binds Ca2+ mostly through main-chain carbonyl groups that which is specific to S100 proteins. Consequently, S100 proteins have a weaker Ca2+ affinity than typical Ca2+ sensors such as calmodulin (Donato, 2003).
An important posttranslational modification of S100A9 represents the phosphorylation of threonine at position 113. It can be phosphorylated upon PMN activation, and phosphorylation of this residue is specifically regulated by the Ca2+-ionophore, ionomycin. Recent studies give evidence for S100A9 being a p38 MAPK substrate in human neutrophils (Lominadze et al., 2005). This phosphorylation is involved in translocation and functional events.
In vivo and in vitro experiments have shown that S100 proteins form homo-, hetero- and oligomeric assemblies (Hunter and Chazin, 1998; Osterloh et al., 1998; Pröpper et al., 1999; Moroz et al., 2003). Together with their specific cell- and tissue-expression patterns, the structural variations, and the different metal ion binding properties (Ca2+, Zn2+ and Cu2+) the S100 protein complexes might be functionally diversified. S100A9 preferentially interacts with S100A8.
It is worthwhile mentioning that the murine analogs display a stronger tendency to form homodimeric protein complexes. In view of the formation of different tertiary structures with putative distinct functions it is tempting to speculate that S100A8 and/or A9 have different functions in mouse and man.
Expression S100A9 is mainly expressed in cells of the myeloid lineage, however, its gene expression is induced in epithelial cells in response to stress, in specific conditions such as wound healing, UV exposition, abundant in psoriais keratinocytes, differentially expressed in several cancers.
Localisation Mostly cytoplasmic, but also at membranes and cytoskeleton.
In resting phagocytes the S100A8/A9 protein complex is mainly located in the cytosol. Upon cellular activation the protein complex is either translocated to cytoskeleton and plasma membrane or released into the extracellular environment.
The translocation pathways occur upon the elevation of the intracellular calcium level (Roth et al., 1993). At a later time point, the S100A8/A9 heterodimers can be detected on the surface of monocytes (Bhardwaj et al., 1992). The mechanism by which the S100A8/A9 heterodimer penetrates the plasma membrane remains unclear since the S100 proteins lack a transmembrane signaling region.
The secretion pathway relies on the activation of protein kinase C. This pathway differs from the classical as well as the alternative secretion pathways of cytokines (Moqbel and Coughlin, 2006). It has been demonstrated that this novel secretion pathway is energy-consuming and depends on an intact microtubule network (Murao et al., 1990; Rammes et al., 1997).
Recent investigations give evidence that interaction of S100A8/A9 with annexin-6 is involved in surface expression and release of S100A8/A9 (Bode et al., 2008). Annexins are another class of Ca2+-regulated proteins. They are characterized by the unique architecture of their Ca2+-binding sites, which enables them to peripherally dock onto negatively charged membrane surfaces in their Ca2+-bound conformation. This property links annexins to many membrane-related events such as certain exocytic and endocytic transport steps. This is an interesting finding since S100A8 and S100A9 are expressed in cancerous cells of secretory tissues as breast and prostate. Cells originating from such glandular tissues are rich in membrane structures, suggesting that membrane-associated molecular targets for the S100A8/A9 proteins could be potentially found in these cells.
Recent investigations also demonstrated the association of S100A8/A9 with cholesterol-enriched membrane microdomains (lipid rafts) (Nacken et al., 2004). This observation is in agreement with the enhancing effect of S100A8/A9 on NADPH oxidase since the formation of the oxidase complex takes place at lipid rafts.
Function Intra- as well as extracellular roles have been proposed for the S100 proteins.

Intracellular activities of S100A8/A9
In the intracellular milieu, S100 proteins are considered as calcium sensors changing their conformation in response to calcium influx and then mediating calcium signals by binding to other intracellular proteins. In a mouse knock-out model chemokine-induced down regulation of the cytosolic Ca2+-level was detected (Nacken et al., 2005).
After calcium binding, the S100A8/A9 protein complex binds specifically polyunsaturated fatty acids. S100A8/A9 represents the exclusive arachidonic acid-binding capacity in the neutrophil cytosol (Kerkhoff et al., 1999), and participates in NADPH oxidase activation by transferring arachidonic acid to membrane-bound gp91phox during interactions with two cytosolic oxidase activation factors, p67phox and Rac-2. The functional relevance of S100A8/A9 in the phagocyte NADPH oxidase activation was demonstrated by the impairment of NADPH oxidase activity in neutrophil-like NB4 cells, after specifically blocking S100A9 expression, and employing bone marrow-derived PMNs from S100A9-/- mice (Kerkhoff et al., 2005).
In accordance to their role in myeloid cells, S100A8/A9 enhances epithelial NADPH oxidases (Benedyk et al., 2007). As a consequence of enhanced ROS levels, NF-kB activation and subsequently TNF-alpha and IL-8 mRNA levels are increased in S100A8/A9-HaCaT keratinocytes, consistent with the view that NF-kB is a redox-sensitive transcription factor. Further consequences of S100A8/A9-mediated NF-kB activation are reduced cell growth, increased expression of differentiation markers, and enhanced PARP cleavage as an indicator of increased cell death (Voss et al., 2011).
In view of the stress response-induced expression of the two S100 proteins in keratinocytes these findings have great implications for tissue remodeling and repair. For example, keratinocytes acquire an activated state after cutaneous wounding in which proliferation is favored over differentiation in order to replenish the lost material and rapidly close the site of injury. Thus, it is likely to hypothesize that S100A8/A9-mediated growth reduction is required for the upcoming cell fate decision of damaged cells, i.e. for a survival phase to be followed by differentiation, proliferation, or apoptosis. These data have also an impact on tumorigenesis since S100 gene expression is associated with neoplastic disorders.
In migrating monocytes the S100A8/A9 complex has been found to be associated with cytoskeletal tubulin and to modulate transendothelial migration (Vogl et al., 2004). Investigations using two different mouse knock-out models demonstrated no obvious phenotype (Manitz et al., 2003; Hobbs et al., 2003). However, reduced migration of S100A9-deficient neutrophils and decreased surface expression of CD11b, which belongs to the integrin family, were observed upon in vitro stimulation.

Extracellular activities of S100A8/A9
The S100/calgranulins display antimicrobial activity by depriving bacterial pathogens of essential trace metals such as Zn2+ and Mn2+ (Steinbakk et al., 1990; Murthy et al., 1993; Clohessy and Golden, 1995; Sohnle et al., 2000). In the context of inflammation, it has been proposed that S100A8/A9 is massively released when neutrophils die to provide a growth-inhibitory type of host defense that is adjunctive to the usual microbicidal functions by binding metals other than Ca2+ (Corbin et al., 2008).
In addition, S100/calgranulins serve as leukocyte chemoattractants (Lackmann et al., 1992; Lackmann et al., 1993; Kocher et al., 1996; Lim et al., 2008). Murine S100A8 has potent chemotactic activity for neutrophils and monocytes in vitro and in vivo (Lackmann et al., 1992). In contrast, human S100A8 displays only weak leukocyte chemotactic activity in vitro and in vivo (Lackmann et al., 1993). Detailed analysis revealed that the hinge region contributes to the chemotactic activity of murine, but not human S100A8. These data questioned whether the proteins are orthologs since there is a high degree of homology between murine and human S100A8 but a functional divergence. Intriguingly, human S100A12 is chemotactic and the hinge region of human S100A12 has been implicated herein (Yang et al., 2001). Thus, the functional and sequence divergence suggested complex evolution of the S100 family in mammals.
The putative pro-inflammatory functions of S100A8 and S100A9 have recently been investigated in two different mouse knock-out models. S100A9 deficiency did not result in an obvious phenotype (Manitz et al., 2003; Hobbs et al., 2003). However, reduced migration of S100A9-deficient neutrophils and decreased surface expression of CD11b, which belongs to the integrin family, were observed upon in vitro stimulation. In addition, chemokine-induced down regulation of the cytosolic Ca2+-level was detected. Obviously, these in vitro effects are compensated by alternative pathways in vivo.
Remarkably, cancer cells utilize S100A8 and S100A9 as guidance for the adhesion and invasion of disseminating malignant cells (Hiratsuka et al., 2006). In the context of malignancy it was reported that S100A8/A9 attracts Mac-1+ myeloid cells to the lung tissue. Recruited Mac-1+ myeloid cells in lung in turn produce S100A8/A9 in response to primary malignant cells in a so called "premetastatic phase". This phase shows the general characteristics of an inflammation state which facilitates the micro-environmental changes required for the migration and implantation of primary tumor cells to lung tissue. After preparation of the target tissue for accepting the malignant cells, tumor cells mimic Mac-1+ myeloid cells in response to S100A8/A9 chemotactic signaling and migrate to lung. So, it seems that tumor cells and Mac-1+ myeloid cells utilize a common pathway for migration to lung which involves the activation of mitogen-activated protein kinase pathway (Hiratsuka et al., 2006). These findings suggest S100A8/A9 as an attractive target for the development of strategies counteracting tumor metastasizing to certain organs.
S100A8 and S100A9 have been identified as important endogenous damage-associated molecular pattern (DAMP) proteins. Although receptors for S100A8/A9 are still largely uncharacterized, more recent findings support the notion that they function as potent ligands of pattern-recognition receptors, such as the toll-like receptor 4 (TLR4) (Vogl et al., 2007) and the receptor for advanced glycation end products (RAGE) (Srikrishna and Freeze, 2009).
The S100/calgranulins display cytokine-like functions, including activation of the receptor for advanced glycation endproducts (RAGE) (Hofmann et al., 1999; Herold et al., 2007). RAGE is a member of the immunoglobulin superfamily and present on numerous cell types. It has been shown to play crucial roles in a variety of pathophysiological situations, such as wound healing, atherosclerotic lesion development, tumor growth and metastasis, systemic amyloidosis, and Alzheimer disease (Bierhaus et al., 2005). RAGE/S100 interaction has been considered a very attractive model to explain how RAGE and its proinflammatory ligand contribute to the pathophysiology of several inflammatory diseases.
Beside the above mentioned receptors a number of other cell surface binding sites specific for S100A8/A9 have been reported, such as novel carboxylated glycans (Srikrishna et al., 2001), heparan sulfate glycosaminoglycans (Robinson et al., 2002), beta2-integrin (Newton and Hogg, 1998), and the fatty acid transporter FAT/CD36 (Kerkhoff et al., 2001). Therefore, the cell surface receptor of S100A8/A9 is still in debate.
Interestingly, the growth-stimulatory activity of S100A8/A9 has been demonstrated to be mediated by binding to the receptor of advanced glycation end products (RAGE) (Ghavami et al., 2008b; Turovskaya et al., 2008; Gebhardt et al., 2008). It is likely to speculate that the selective up-regulation of S100 proteins may be of importance for survival and proliferation of metastasizing cancer cells.
S100A8/A9 complexes that are secreted from phorbolester-stimulated neutrophil-like HL-60 cells have been shown to carry the eicosanoid precursor arachidonic acid (Kerkhoff et al., 1999). The S100A8/A9-arachidonic acid complex is recognized by the fatty acid transporter FAT/CD36, and the fatty acid is rapidly taken up (Kerkhoff et al., 2001). Endothelial cells as well as neutrophils themselves utilize both endogenous and exogenous arachidonic acid for transcellular production of eicosanoids (Sala et al., 1999). Therefore, the secreted S100A8/A9-AA complex may serve as a transport protein to move AA to its target cells. This may represent a mechanism by which AA-derived eicosanoids are synthesized in a cooperative manner between different cell species due to environmental cues.
S100A8/A9 displays apoptosis-inducing activity against various tumor cells (Yui et al., 1995; Yui et al., 2002; Ghavami et al., 2004; Ghavami et al., 2008a; Kerkhoff and Ghavami, 2009; Ghavami et al., 2009; Ghavami et al., 2010). It was speculated that this activity was due to the ability to bind divalent metal ions including Zn2+, Mn2+ and Cu2+ at sites that are distinct from Ca2+-binding sites. However, a number of recent reports now indicate that S100A8/A9 exerts its activity by both chelation of trace metal ions such as Zn2+ and cell surface receptor mediated pathways.
Although a number of receptors have been shown to bind S100A8/A9, the nature of the receptor involved in S100A8/A9-induced cell death remains to be elucidated. Experiments with certain cell lines either deficient for or over expressing components of the death signaling machinery as well as RAGE gene silencing and blocking RAGE-specific antibody approaches excluded both RAGE and the classical death receptor to be involved in S100A8/A9-induced cell death, even though S100A8/A9 can specifically bind to cancer cells and RAGE mediates the growth-promoting activity obvious at low micromolar concentrations of S100A8/A9. Clearly, investigations to identify the receptor involved in S100A8/A9-induced cell death are critical.

Homology Overall, the S100 proteins share significant sequential homology in the EF-hand motifs, but are least conserved in the hinge region. This region is proposed to provide for specific interaction with target proteins (Groves et al., 1998; Zimmer et al., 2003; Santamaria-Kisiel et al., 2006; Fernandez-Fernandez et al., 2008; van Dieck et al., 2009). The availability of high-resolution S100-target structures has highlighted important structural features that contribute to S100 protein functional specificity (Bhattacharya et al., 2003).
The functional diversification of S100 proteins is achieved by their specific cell- and tissue-expression patterns, structural variations, different metal ion binding properties (Ca2+, Zn2+ and Cu2+) as well as their ability to form homo-, hetero- and oligomeric assemblies (Hunter and Chazin, 1998; Osterloh et al., 1998; Pröpper et al., 1999; Tarabykina et al., 2001; Moroz et al., 2003; Fritz et al., 2010). Although the function of S100 proteins in cancer cells in most cases is still unknown, the specific expression patterns of these proteins are a valuable diagnostic tool.

Implicated in

Note
  
Entity General note
Note Comparative and functional genomics have revealed that a number of S100 proteins are found to be differentially expressed in cancer cells. Several of these have been associated with tumor development, cancer invasion or metastasis in recent studies (for review see Salama et al., 2008).
S100A8 and S100A9 are abundant in cells of the myeloid lineage, are released from activated phagocytes and display intra- and extracellular functions. Their expression is ubiquitously observed in the squamous epithelia under normal, inflammatory and cancerous conditions. Immunohistochemical investigations have shown that the S100 proteins are over expressed in skin cancers, pulmonary adenocarcinoma, pancreatic adenocarcinoma, bladder cancers, ductal carcinoma of the breast, and prostate adenocarcinoma. In contrast, S100A8 and S100A9 are down-regulated in esophageal squamous cell carcinomas. Furthermore, plasma levels of S100A8/A9 are elevated in patients suffering from various cancers. Insofar, S100A8 and S100A9 might represent novel diagnostic markers for some carcinomas.
S100A8 and S100A9 have been suggested to have potential roles in carcinogenesis and tumor progression. However, the biological role of S100A8/A9 remains to be elucidated. It is conceivable that S100A8 and S100A9 modulate signal pathways to directly promote invasion, migration and metastasis, probably via activation of NF-kB, Akt or MAP kinases.
In the last decade the concept of the functional relationship between inflammation and cancer has been developed that is based on numerous findings, ranging from epidemiological studies to molecular analyses of mouse models (Coussens and Werb, 2002). In this concept, the generation of an inflammatory microenvironment supports tumorigenesis by promoting cancer cell survival, proliferation, migration, and invasion. Although it is clear that inflammation alone does not cause cancer, it is evident that an environment that is rich in inflammatory cells, growth factors, activated stroma, and DNA-damage-promoting agents certainly potentiates and/or promotes neoplastic risk. In addition, many cancers arise from sites of infection, chronic irritation and inflammation.
Recent data have expanded our knowledge demonstrating that specific soluble factors released from primary tumors induce the S100A8 and S100A9 gene expression in the target tissue. After secretion S100A8 and S100A9 might display chemokine- and cytokine-like properties that promote invasion, migration and metastasis. These data indicate that tumor cells are able to reprogram some of the signaling molecules of the innate immune system. These insights are fostering new anti-inflammatory therapeutic approaches to cancer development.
  
  
Entity Skin cancer
Note The expression of S100A8 and S100A9 in epithelial cells was first detected in the squamous epithelia (Gabrielsen et al., 1986). Normal S100A8 and S100A9 are expressed at minimal levels in the epidermis. However, their expression is induced in inflammatory and cancerous conditions, and pro-inflammatory cytokines such as TNF-alpha and IL1 beta are involved herein.
Gene expression analysis in a mouse model of chemically induced skin carcinogenesis identified a large set of novel tumor-associated genes including S100A8 (Hummerich et al., 2006). The data was confirmed by in situ hybridization and immunofluorescence analysis on mouse tumor sections, in mouse keratinocyte cell lines that form tumors in vivo, and in human skin tumor specimens.
However, conflicting results have been published concerning S100 expression in skin cancer. For instance, esophageal squamous cell carcinoma (ESCC) is one of the most common cancers worldwide. DNA microarray data analysis revealed that S100A8 and S100A9 were significantly down regulated in human ESCC versus the normal counterparts (Zhi et al., 2003). Interestingly, among the 42 genes either up regulated or down regulated in tumors, as compared to normal esophageal squamous epithelia, nine of the altered expression genes were related to arachidonic acid (AA) metabolism, suggesting that AA metabolism pathway and its altered expression may contribute to esophageal squamous cell carcinogenesis. Similar data were obtained by Ji et al. (2004). They investigated the differential expression of the S100 gene family at the RNA level in human ESCC. Eleven out of 16 S100 genes were significantly down regulated in ESCC versus the normal counterparts. Only the S100A7 gene was found to be markedly up regulated. Another study demonstrated that poorly differentiated ESCC displayed a stronger decrease in S100A8 and S100A9 expression than well and moderately differentiated tumors, with a correlation between protein level and histopathological grading (Kong et al., 2004). These findings suggest that decreased expression of S100A8 and S100A9 might play an important role in the ESCC pathogenesis, being particularly associated with poor differentiation of tumor cells.
  
  
Entity Lung adenocarcinomas
Note S100A9 over expression has been detected in various carcinomas of glandular cell origin, and its expression has been associated with poor tumor differentiation. Similarly, S100A9 immunopositivity was also detected in pulmonary adenocarcinoma cell lines and resected pulmonary adenocarcinoma (Arai et al., 2001). Examination of the relation of S100A9 expression to tumor differentiation showed that the expression rate in pulmonary adenocarcinoma showed higher correlation in poorly differentiated carcinomas.
Another study confirmed these data (Su et al., 2010). Immunohistochemical staining of both S100 proteins showed a significant up-regulation in lung cancer tissue, and quantitative PCR revealed significantly higher levels of S100A8 and S100A9 mRNA transcripts in lung cancer tissues. Moreover, this study correlates S100A9 expression with inflammation and other clinical features (Su et al., 2010).
Primary tumors influence the environment in the lungs before metastasis. They release specific soluble factors that prepare the premetastatic niche for the engraftment of tumor cells. In several studies it has been shown that tumor cells induce both expression and secretion of S100A8 and S100A9 in the target organ that display a promoting role in cancer cell survival, proliferation, migration, and invasion (Hiratsuka et al., 2002; Hiratsuka et al., 2006; Hiratsuka et al., 2008; Saha et al., 2010).
Microarray analysis of lungs from tumor-bearing and non-bearing mice revealed the strong up-regulation of a number of genes including S100A8 and S100A9 (Hiratsuka et al. 2002). Their expression in Mac 1+-myeloid cells and endothelial cells was induced by factors such as vascular endothelial growth factor A (VEGF-A), tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta), both in vitro and in vivo (Hiratsuka et al., 2006). Remarkably, anti-S100A8 neutralizing antibody treatment blocked metastasis. S100A8 and S100A9 were shown to induce the expression of serum amyloid A (SAA) that attracted Mac 1+-myeloid cells in the premetastatic lung (Hiratsuka et al., 2008). These studies demonstrated that lung cancer cells utilize S100A8 and S100A9 as guidance for the adhesion and invasion of disseminating malignant cells.
  
  
Entity Pancreatic adenocarcinoma
Note Patients with ductal adenocarcinoma of the pancreas have a dismal prognosis. Thus, there is an urgent need for early detection markers and the development of immunotherapeutical approaches concentrating on the induction and enhancement of immune responses against tumors. Proteomic analyses of pancreatic adenocarcinoma, normal adjacent tissues, pancreatitis, and normal pancreatic tissues revealed a number of differentially expressed genes (Shen et al., 2004). S100A8 was found to be specifically over expressed in tumors compared with normal and pancreatitis tissues.
These data are in accordance with another study (Sheikh et al., 2007). Strong expression of S100A8 and S100A9 was found in tumor-associated stroma but not in benign or malignant epithelia. Further analyses identified stromal CD14+ CD68- monocytes/macrophages as source for S100 expression. Interestingly, the number of S100A8-positive cells in the tumor microenvironment negatively correlated with the expression of the tumor suppressor protein, Smad4. The number of S100A9-positive cells was not altered in Smad4-negative or Smad4-positive tumors.
A similar correlation was found in colorectal cancer tumors (Ang et al., 2010). The number of stromal S100A8- and S100A9-positive cells was associated with the presence or absence of Smad4. Smad4-negative tumors showed enhanced numbers of S100A8/A9 stroma cells, and the corresponding patients had a poor survival prognosis. Investigation of the underlying molecular mechanisms revealed that both migration and proliferation was enhanced in response to exogenous S100A8 and S100A9, irrespective of Smad4-presence. However, depletion of Smad4 resulted in loss of responsiveness to exogenous S100A8, but not S100A9. Vice versa, Smad4 expression in Smad4-negative cells enhanced the responsive-ness to S100A8 and S100A9. Further analyses give evidence that similar to TGF-beta, S100A8 and S100A9 induce the phosphorylation of both Smad2 and Smad3 that was blocked by a RAGE-specific antibody. These data point to a functional relationship between inflammation and tumorigenesis.
  
  
Entity Bladder cancers
Note Gene expression profiles revealed that thirteen members of the S100 gene family were differentially expressed in human bladder cancers. S100A8 and S100A9 were found to be over expressed (Yao et al., 2007).
Another study investigated S100A9 expression and DNA methylation in urothelial cancer cell lines and cancer tissue (Dokun et al., 2008). Expression of S100A9 was found to be generally elevated in the tumor tissues but S100A9 was weakly expressed in most cancer cell lines. The S100A9 promoter contains 6 CpG sites, and its methylation state was unrelated to the variable expression. It has been hypothesized that over expression of genes is the consequence of DNA hypomethylation, however, DNA methylation and gene expression are less strictly related for those genes having promoters within CpG-islands. Alternatively, the increased S100A9 gene expression may be related to that of other immune-related genes in the carcinoma cell cultures. This is sustained by the facts that S100A9 is secreted by epithelial and other cell types to modulate inflammatory reactions as well as to promote cancer proliferation and metastasis.
Two recent studies propose S100A8 and S100A9 gene expression as prognostic value for bladder cancer (Minami et al., 2010; Ha et al., 2010). By proteomic analysis of pre- and postoperative sera from bladder cancer patients S100A8 and S100A9 were identified as tumor-associated proteins (Minami et al., 2010). Interestingly, S100A8 expression was associated with bladder wall muscle invasion of the tumor and cancer-specific survival while S100A9 expression was associated with the tumor grade. In addition, the expression of both proteins S100A8/A9 was correlated with recurrence-free survival.
In another study it was evaluated whether S100A8 is a prognostic value for non-muscle-invasive bladder cancer (NMIBC) (Ha et al., 2010). S100A8 expression was evaluated in a total of 103 primary NMIBC samples by quantitative PCR. The mRNA expression levels of S100A8 were significantly related to the progression of NMIBC, suggesting that S100A8 might be a useful prognostic marker for disease progression of NMIBC.
  
  
Entity Breast cancers
Note S100A8 and S100A9 are expressed in breast cancers (Cross et al., 2005), especially in invasive breast carcinoma (Arai et al., 2004). By immunohistochemical analyses a strong S100A9 immunoreactivity has been demonstrated in invasive as well as non-invasive ductal carcinoma. No immunopositive reaction was observed in invasive lobular carcinomas, and no significant differences were detected in the number of myelomonocytic cells expressing S100A9. These data give evidence that S100A9 in glandular epithelial cells is newly expressed under cancerous conditions and is over-expressed in poorly differentiated adenocarcinoma (Arai et al., 2004). Further analyses target on the relationship between S100A8/A9 expression and pathological parameters that reflect the aggressiveness of carcinoma. The immunopositivity for S100A8/A9 correlated with poor tumor differentiation, mitotic activity, HER2/neu over expression, poor pT categories, node metastasis, and poor pStage, but not with vessel invasion. These data may indicate that S100A8 and S100A9 over expression should be considered marker of poor prognosis in invasive breast ductal carcinoma (Arai et al., 2008).
By analyses of ductal carcinoma in situ and invasive ductal carcinoma of the breast S100A9 has been demonstrated to be most abundantly expressed in the invasive tumor (Seth et al., 2003). Therefore, the expression of S100A8 and S100A9 has been correlated with the degree of noninvasive / invasive behavior. There are conflicting data concerning this correlation. For instance, non-invasive MCF-7 breast cancer cells do not express S100A9, and its gene expression is induced by cytokine oncostatin M through the STAT3 signaling cascade (Li et al., 2004). However, non-invasive MDA-MB-468 cells are abundant for both S100 proteins (Bode et al., 2008) and invasive breast cancer cells MDA-MB-231 show low transcript level of S100A9 (Nagaraja et al., 2006).
  
  
Entity Thyroid carcinoma
Note Similar to other carcinomas of glandular cell origin, expression of S100A8 and S100A9 is significantly linked to dedifferentiation of thyroid carcinoma (Ito et al., 2005; Ito et al., 2009). S100A8 and S100A9 immunreactivity was found in all undifferentiated carcinomas examined, while papillary carcinoma, follicular carcinoma, follicular adenoma and medullary carcinoma and normal follicules were negative for both proteins. Further analyses revealed that S100A9 is a useful marker for discriminating intrathyroid epithelial tumor from squamous cell carcinoma or undifferentiated carcinoma with squamoid component (Ito et al., 2006).
  
  
Entity Prostate cancer
Note Increased levels of S100A8, S100A9, and RAGE have been reported in prostatic intra epithelial neoplasia and preferentially in high-grade adenocarcinomas, whereas benign tissue was negative or showed weak expression of the proteins. The three proteins showed a strong overlap in the expression pattern. S100A9 serum level was significantly elevated in cancer patients compared with benign prostatic hyperplasia patients or healthy individuals. Therefore, S100A8 and S100A9 might represent novel diagnostic markers for prostate cancer and benign prostate hyperplasia (Hermani et al., 2005).
In further analyses it has been demonstrated that S100A8 and S100A9 are secreted by prostate cancer cells, and extracellular S100A8/A9 stimulates migration of benign prostatic cells in vitro by activation of NF-kB and increased phosphorylation of p38 and p44/p42 MAP kinases. Immunofluorescence analyses give evidence for a RAGE-mediated response (Hermani et al., 2006).
The significance of being diagnostic markers for prostate cancer has been questioned by Ludwig et al. (2007). Their re-evaluation study has shown that S100A8/A9 did not improve the differentiation between patients with and without prostate cancer. The data give no evidence for the replacement of the established marker PSA by S100A8/A9.
  

Bibliography

Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells.
Ang CW, Nedjadi T, Sheikh AA, Tweedle EM, Tonack S, Honap S, Jenkins RE, Park BK, Schwarte-Waldhoff I, Khattak I, Azadeh B, Dodson A, Kalirai H, Neoptolemos JP, Rooney PS, Costello E.
Carcinogenesis. 2010 Sep;31(9):1541-51. Epub 2010 Jul 9.
PMID 20622003
 
S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast.
Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R.
Curr Cancer Drug Targets. 2008 Jun;8(4):243-52.
PMID 18537548
 
S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation.
Arai K, Teratani T, Kuruto-Niwa R, Yamada T, Nozawa R.
Eur J Cancer. 2004 May;40(8):1179-87.
PMID 15110881
 
HaCaT keratinocytes overexpressing the S100 proteins S100A8 and S100A9 show increased NADPH oxidase and NF-kappaB activities.
Benedyk M, Sopalla C, Nacken W, Bode G, Melkonyan H, Banfi B, Kerkhoff C.
J Invest Dermatol. 2007 Aug;127(8):2001-11. Epub 2007 Apr 12.
PMID 17429438
 
The calcium-binding proteins MRP8 and MRP14 form a membrane-associated heterodimer in a subset of monocytes/macrophages present in acute but absent in chronic inflammatory lesions.
Bhardwaj RS, Zotz C, Zwadlo-Klarwasser G, Roth J, Goebeler M, Mahnke K, Falk M, Meinardus-Hager G, Sorg C.
Eur J Immunol. 1992 Jul;22(7):1891-7.
PMID 1378023
 
Structure of the Ca2+/S100B/NDR kinase peptide complex: insights into S100 target specificity and activation of the kinase.
Bhattacharya S, Large E, Heizmann CW, Hemmings B, Chazin WJ.
Biochemistry. 2003 Dec 16;42(49):14416-26.
PMID 14661952
 
Advanced glycation end product receptor-mediated cellular dysfunction.
Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP.
Ann N Y Acad Sci. 2005 Jun;1043:676-80. (REVIEW)
PMID 16037292
 
Interaction between S100A8/A9 and annexin A6 is involved in the calcium-induced cell surface exposition of S100A8/A9.
Bode G, Luken A, Kerkhoff C, Roth J, Ludwig S, Nacken W.
J Biol Chem. 2008 Nov 14;283(46):31776-84. Epub 2008 Sep 11.
PMID 18786929
 
IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes.
Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F.
J Immunol. 2005 Mar 15;174(6):3695-702.
PMID 15749908
 
Cluster analysis of S100 gene expression and genes correlating to psoriasin (S100A7) expression at different stages of breast cancer development.
Carlsson H, Petersson S, Enerback C.
Int J Oncol. 2005 Dec;27(6):1473-81.
PMID 16273201
 
Calprotectin-mediated zinc chelation as a biostatic mechanism in host defence.
Clohessy PA, Golden BE.
Scand J Immunol. 1995 Nov;42(5):551-6.
PMID 7481561
 
Metal chelation and inhibition of bacterial growth in tissue abscesses.
Corbin BD, Seeley EH, Raab A, Feldmann J, Miller MR, Torres VJ, Anderson KL, Dattilo BM, Dunman PM, Gerads R, Caprioli RM, Nacken W, Chazin WJ, Skaar EP.
Science. 2008 Feb 15;319(5865):962-5.
PMID 18276893
 
Inflammation and cancer.
Coussens LM, Werb Z.
Nature. 2002 Dec 19-26;420(6917):860-7. (REVIEW)
PMID 12490959
 
Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers.
Cross SS, Hamdy FC, Deloulme JC, Rehman I.
Histopathology. 2005 Mar;46(3):256-69.
PMID 15720411
 
Relationship of SNCG, S100A4, S100A9 and LCN2 gene expression and DNA methylation in bladder cancer.
Dokun OY, Florl AR, Seifert HH, Wolff I, Schulz WA.
Int J Cancer. 2008 Dec 15;123(12):2798-807.
PMID 18803290
 
Intracellular and extracellular roles of S100 proteins.
Donato R.
Microsc Res Tech. 2003 Apr 15;60(6):540-51. (REVIEW)
PMID 12645002
 
Members of the S100 family bind p53 in two distinct ways.
Fernandez-Fernandez MR, Rutherford TJ, Fersht AR.
Protein Sci. 2008 Oct;17(10):1663-70. Epub 2008 Aug 11.
PMID 18694925
 
Natural and amyloid self-assembly of S100 proteins: structural basis of functional diversity.
Fritz G, Botelho HM, Morozova-Roche LA, Gomes CM.
FEBS J. 2010 Nov;277(22):4578-90. doi: 10.1111/j.1742-4658.2010.07887.x. (REVIEW)
PMID 20977662
 
Epidermal and dermal distribution of a myelomonocytic antigen (L1) shared by epithelial cells in various inflammatory skin diseases.
Gabrielsen TO, Dale I, Brandtzaeg P, Hoel PS, Fagerhol MK, Larsen TE, Thune PO.
J Am Acad Dermatol. 1986 Aug;15(2 Pt 1):173-9.
PMID 2427557
 
RAGE signaling sustains inflammation and promotes tumor development.
Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, Hess J, Angel P.
J Exp Med. 2008 Feb 18;205(2):275-85. Epub 2008 Jan 21.
PMID 18208974
 
S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis.
Ghavami S, Chitayat S, Hashemi M, Eshraghi M, Chazin WJ, Halayko AJ, Kerkhoff C.
Eur J Pharmacol. 2009 Dec 25;625(1-3):73-83. Epub 2009 Oct 14. (REVIEW)
PMID 19835859
 
S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3.
Ghavami S, Eshragi M, Ande SR, Chazin WJ, Klonisch T, Halayko AJ, McNeill KD, Hashemi M, Kerkhoff C, Los M.
Cell Res. 2010 Mar;20(3):314-31. Epub 2009 Nov 24.
PMID 19935772
 
S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2.
Ghavami S, Kerkhoff C, Chazin WJ, Kadkhoda K, Xiao W, Zuse A, Hashemi M, Eshraghi M, Schulze-Osthoff K, Klonisch T, Los M.
Biochim Biophys Acta. 2008a Feb;1783(2):297-311. Epub 2007 Nov 7.
PMID 18060880
 
S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway.
Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M, Wesselborg S, Kerkhoff C, Los M.
J Leukoc Biol. 2008b Jun;83(6):1484-92. Epub 2008 Mar 13.
PMID 18339893
 
Endothelial-dependent mechanisms of leukocyte adhesion in inflammation and atherosclerosis.
Gimbrone MA Jr, Bevilacqua MP, Cybulsky MI.
Ann N Y Acad Sci. 1990;598:77-85.
PMID 1701076
 
Identification of poly(ADP-ribose)polymerase-1 and Ku70/Ku80 as transcriptional regulators of S100A9 gene expression.
Grote J, Konig S, Ackermann D, Sopalla C, Benedyk M, Los M, Kerkhoff C.
BMC Mol Biol. 2006 Dec 22;7:48.
PMID 17187679
 
A model for target protein binding to calcium-activated S100 dimers.
Groves P, Finn BE, Kuznicki J, Forsen S.
FEBS Lett. 1998 Jan 16;421(3):175-9.
PMID 9468301
 
mRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder Cancer.
Ha YS, Kim MJ, Yoon HY, Kang HW, Kim YJ, Yun SJ, Lee SC, Kim WJ.
Korean J Urol. 2010 Jan;51(1):15-20. Epub 2010 Jan 21.
PMID 20414404
 
Assignment of psoriasin to human chromosomal band 1q21: coordinate overexpression of clustered genes in psoriasis.
Hardas BD, Zhao X, Zhang J, Longqing X, Stoll S, Elder JT.
J Invest Dermatol. 1996 Apr;106(4):753-8.
PMID 8618016
 
Identification of three genes up-regulated in PU.1 rescued monocytic precursor cells.
Henkel GW, McKercher SR, Maki RA.
Int Immunol. 2002 Jul;14(7):723-32.
PMID 12096031
 
S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells.
Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D.
Exp Cell Res. 2006 Jan 15;312(2):184-97. Epub 2005 Nov 17.
PMID 16297907
 
Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer.
Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P, Mayer D.
Clin Cancer Res. 2005 Jul 15;11(14):5146-52.
PMID 16033829
 
Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress.
Herold K, Moser B, Chen Y, Zeng S, Yan SF, Ramasamy R, Emond J, Clynes R, Schmidt AM.
J Leukoc Biol. 2007 Aug;82(2):204-12. Epub 2007 May 18. (REVIEW)
PMID 17513693
 
The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase.
Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, Shibuya M, Akira S, Aburatani H, Maru Y.
Nat Cell Biol. 2008 Nov;10(11):1349-55. Epub 2008 Sep 28.
PMID 18820689
 
Myeloid cell function in MRP-14 (S100A9) null mice.
Hobbs JA, May R, Tanousis K, McNeill E, Mathies M, Gebhardt C, Henderson R, Robinson MJ, Hogg N.
Mol Cell Biol. 2003 Apr;23(7):2564-76.
PMID 12640137
 
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides.
Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM.
Cell. 1999 Jun 25;97(7):889-901.
PMID 10399917
 
Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development.
Hummerich L, Muller R, Hess J, Kokocinski F, Hahn M, Furstenberger G, Mauch C, Lichter P, Angel P.
Oncogene. 2006 Jan 5;25(1):111-21.
PMID 16247483
 
High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14.
Hunter MJ, Chazin WJ.
J Biol Chem. 1998 May 15;273(20):12427-35.
PMID 9575199
 
S100A8 and S100A9 expression is a crucial factor for dedifferentiation in thyroid carcinoma.
Ito Y, Arai K, Nozawa R, Yoshida H, Hirokawa M, Fukushima M, Inoue H, Tomoda C, Kihara M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A.
Anticancer Res. 2009 Oct;29(10):4157-61.
PMID 19846966
 
Usefulness of S100A9 for diagnosis of intrathyroid epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE).
Ito Y, Miyauchi A, Arai K, Nozawa R, Miya A, Kobayashi K, Nakamura Y, Kakudo K.
Pathology. 2006 Dec;38(6):541-4.
PMID 17393982
 
Differential expression of S100 gene family in human esophageal squamous cell carcinoma.
Ji J, Zhao L, Wang X, Zhou C, Ding F, Su L, Zhang C, Mao X, Wu M, Liu Z.
J Cancer Res Clin Oncol. 2004 Aug;130(8):480-6. Epub 2004 Jun 4.
PMID 15185146
 
Innate immunity molecules S100A8/A9 involved in stress response and cancer biology.
Kerkhoff C, Ghavami S.
Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2009; (8)4:279-281.
 
Identification of epithelial and myeloid-specific DNA elements regulating MRP14 gene transcription.
Klempt M, Melkonyan H, Hofmann HA, Sorg C.
J Cell Biochem. 1999 Apr 1;73(1):49-55.
PMID 10088723
 
Functional chemotactic factor CP-10 and MRP-14 are abundant in murine abscesses.
Kocher M, Kenny PA, Farram E, Abdul Majid KB, Finlay-Jones JJ, Geczy C L.
Infect Immun. 1996 Apr;64(4):1342-50.
PMID 8606099
 
Loss of myeloid-related proteins 8 and myeloid-related proteins 14 expression in human esophageal squamous cell carcinoma correlates with poor differentiation.
Kong JP, Ding F, Zhou CN, Wang XQ, Miao XP, Wu M, Liu ZH.
World J Gastroenterol. 2004 Apr 15;10(8):1093-7.
PMID 15069705
 
Transcriptional regulation by C/EBP alpha and -beta in the expression of the gene for the MRP14 myeloid calcium binding protein.
Kuruto-Niwa R, Nakamura M, Takeishi K, Nozawa R.
Cell Struct Funct. 1998 Jun;23(3):109-18.
PMID 9706399
 
Appearance of nuclear factors that interact with genes for myeloid calcium binding proteins (MRP-8 and MRP-14) in differentiated HL-60 cells.
Kuwayama A, Kuruto R, Horie N, Takeishi K, Nozawa R.
Blood. 1993 Jun 1;81(11):3116-21.
PMID 8499645
 
Identification of a chemotactic domain of the pro-inflammatory S100 protein CP-10.
Lackmann M, Rajasekariah P, Iismaa SE, Jones G, Cornish CJ, Hu S, Simpson RJ, Moritz RL, Geczy CL.
J Immunol. 1993 Apr 1;150(7):2981-91.
PMID 8454868
 
Induction of S100A9 gene expression by cytokine oncostatin M in breast cancer cells through the STAT3 signaling cascade.
Li C, Zhang F, Lin M, Liu J.
Breast Cancer Res Treat. 2004 Sep;87(2):123-34.
PMID 15377837
 
S-nitrosylated S100A8: novel anti-inflammatory properties.
Lim SY, Raftery M, Cai H, Hsu K, Yan WX, Hseih HL, Watts RN, Richardson D, Thomas S, Perry M, Geczy CL.
J Immunol. 2008 Oct 15;181(8):5627-36.
PMID 18832721
 
Myeloid-related protein-14 is a p38 MAPK substrate in human neutrophils.
Lominadze G, Rane MJ, Merchant M, Cai J, Ward RA, McLeish KR.
J Immunol. 2005 Jun 1;174(11):7257-67.
PMID 15905572
 
Histidine-based zinc-binding sequences and the antimicrobial activity of calprotectin.
Loomans HJ, Hahn BL, Li QQ, Phadnis SH, Sohnle PG.
J Infect Dis. 1998 Mar;177(3):812-4.
PMID 9498472
 
S100A8, S100A9, and the S100A8/A9 complex in circulating blood are not associated with prostate cancer risk-A re-evaluation study.
Ludwig S, Stephan C, Lein M, Loening SA, Jung K.
Prostate. 2007 Sep 1;67(12):1301-7.
PMID 17626245
 
Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro.
Manitz MP, Horst B, Seeliger S, Strey A, Skryabin BV, Gunzer M, Frings W, Schonlau F, Roth J, Sorg C, Nacken W.
Mol Cell Biol. 2003 Feb;23(3):1034-43.
PMID 12529407
 
The gene encoding the myeloid-related protein 14 (MRP14), a calcium-binding protein expressed in granulocytes and monocytes, contains a potent enhancer element in the first intron.
Melkonyan H, Hofmann HA, Nacken W, Sorg C, Klempt M.
J Biol Chem. 1998 Oct 9;273(41):27026-32.
PMID 9756953
 
Proteomic study of sera from patients with bladder cancer: usefulness of S100A8 and S100A9 proteins.
Minami S, Sato Y, Matsumoto T, Kageyama T, Kawashima Y, Yoshio K, Ishii J, Matsumoto K, Nagashio R, Okayasu I.
Cancer Genomics Proteomics. 2010 Jul-Aug;7(4):181-9.
PMID 20656984
 
Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex ("epidermal differentiation complex") on human chromosome 1q21.
Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A.
J Invest Dermatol. 1996 May;106(5):989-92.
PMID 8618063
 
In vitro antimicrobial activity of the human neutrophil cytosolic S-100 protein complex, calprotectin, against Capnocytophaga sputigena.
Miyasaki KT, Bodeau AL, Murthy AR, Lehrer RI.
J Dent Res. 1993 Feb;72(2):517-23.
PMID 8423249
 
Differential secretion of cytokines.
Moqbel R, Coughlin JJ.
Sci STKE. 2006 Jun 6;2006(338):pe26. (REVIEW)
PMID 16757734
 
Multiple structural states of S100A12: A key to its functional diversity.
Moroz OV, Dodson GG, Wilson KS, Lukanidin E, Bronstein IB.
Microsc Res Tech. 2003 Apr 15;60(6):581-92. (REVIEW)
PMID 12645006
 
A protein complex expressed during terminal differentiation of monomyelocytic cells is an inhibitor of cell growth.
Murao S, Collart F, Huberman E.
Cell Growth Differ. 1990 Oct;1(10):447-54.
PMID 2278876
 
In vitro candidastatic properties of the human neutrophil calprotectin complex.
Murthy AR, Lehrer RI, Harwig SS, Miyasaki KT.
J Immunol. 1993 Dec 1;151(11):6291-301.
PMID 8245468
 
Molecular analysis of the mouse S100A9 gene and evidence that the myeloid specific transcription factor C/EBPepsilon is not required for the regulation of the S100A9/A8 gene expression in neutrophils.
Nacken W, Lekstrom-Himes JA, Sorg C, Manitz MP.
J Cell Biochem. 2001;80(4):606-16.
PMID 11169745
 
S100A9 deficiency alters adenosine-5'-triphosphate induced calcium signalling but does not generally interfere with calcium and zinc homeostasis in murine neutrophils.
Nacken W, Mooren FC, Manitz MP, Bode G, Sorg C, Kerkhoff C.
Int J Biochem Cell Biol. 2005 Jun;37(6):1241-53. Epub 2005 Jan 27.
PMID 15778088
 
The myeloid expressed EF-hand proteins display a diverse pattern of lipid raft association.
Nacken W, Sorg C, Kerkhoff C.
FEBS Lett. 2004 Aug 13;572(1-3):289-93.
PMID 15304364
 
Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics.
Nagaraja GM, Othman M, Fox BP, Alsaber R, Pellegrino CM, Zeng Y, Khanna R, Tamburini P, Swaroop A, Kandpal RP.
Oncogene. 2006 Apr 13;25(16):2328-38.
PMID 16314837
 
The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils.
Newton RA, Hogg N.
J Immunol. 1998 Feb 1;160(3):1427-35.
PMID 9570563
 
Hydrophobic residues in the C-terminal region of S100A1 are essential for target protein binding but not for dimerization.
Osterloh D, Ivanenkov VV, Gerke V.
Cell Calcium. 1998 Aug;24(2):137-51.
PMID 9803314
 
Analysis of the MRP8-MRP14 protein-protein interaction by the two-hybrid system suggests a prominent role of the C-terminal domain of S100 proteins in dimer formation.
Propper C, Huang X, Roth J, Sorg C, Nacken W.
J Biol Chem. 1999 Jan 1;274(1):183-8.
PMID 9867828
 
Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway.
Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C.
J Biol Chem. 1997 Apr 4;272(14):9496-502.
PMID 9083090
 
Clustered organization of S100 genes in human and mouse.
Ridinger K, Ilg EC, Niggli FK, Heizmann CW, Schafer BW.
Biochim Biophys Acta. 1998 Dec 10;1448(2):254-63.
PMID 9920416
 
The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells.
Robinson MJ, Tessier P, Poulsom R, Hogg N.
J Biol Chem. 2002 Feb 1;277(5):3658-65. Epub 2001 Nov 26.
PMID 11723110
 
MRP8 and MRP14, S-100-like proteins associated with myeloid differentiation, are translocated to plasma membrane and intermediate filaments in a calcium-dependent manner.
Roth J, Burwinkel F, van den Bos C, Goebeler M, Vollmer E, Sorg C.
Blood. 1993 Sep 15;82(6):1875-83.
PMID 8400238
 
Lack of an endogenous anti-inflammatory protein in mice enhances colonization of B16F10 melanoma cells in the lungs.
Saha A, Lee YC, Zhang Z, Chandra G, Su SB, Mukherjee AB.
J Biol Chem. 2010 Apr 2;285(14):10822-31. Epub 2010 Jan 29.
PMID 20118237
 
Differential metabolism of exogenous and endogenous arachidonic acid in human neutrophils.
Sala A, Zarini S, Folco G, Murphy RC, Henson PM.
J Biol Chem. 1999 Oct 1;274(40):28264-9.
PMID 10497182
 
A review of the S100 proteins in cancer.
Salama I, Malone PS, Mihaimeed F, Jones JL.
Eur J Surg Oncol. 2008 Apr;34(4):357-64. Epub 2007 Jun 13.
PMID 17566693
 
Calcium-dependent and -independent interactions of the S100 protein family.
Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS.
Biochem J. 2006 Jun 1;396(2):201-14. (REVIEW)
PMID 16683912
 
Evidence for differential S100 gene over-expression in psoriatic patients from genetically heterogeneous pedigrees.
Semprini S, Capon F, Tacconelli A, Giardina E, Orecchia A, Mingarelli R, Gobello T, Zambruno G, Botta A, Fabrizi G, Novelli G.
Hum Genet. 2002 Oct;111(4-5):310-3. Epub 2002 Aug 21.
PMID 12384771
 
Gene expression profiling of ductal carcinomas in situ and invasive breast tumors.
Seth A, Kitching R, Landberg G, Xu J, Zubovits J, Burger AM.
Anticancer Res. 2003 May-Jun;23(3A):2043-51.
PMID 12894577
 
The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells.
Sheikh AA, Vimalachandran D, Thompson CC, Jenkins RE, Nedjadi T, Shekouh A, Campbell F, Dodson A, Prime W, Crnogorac-Jurcevic T, Lemoine NR, Costello E.
Proteomics. 2007 Jun;7(11):1929-40.
PMID 17469085
 
Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry.
Shen J, Person MD, Zhu J, Abbruzzese JL, Li D.
Cancer Res. 2004 Dec 15;64(24):9018-26.
PMID 15604267
 
Antimicrobial activity of an abundant calcium-binding protein in the cytoplasm of human neutrophils.
Sohnle PG, Collins-Lech C, Wiessner JH.
J Infect Dis. 1991 Jan;163(1):187-92.
PMID 1984467
 
Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14).
Sohnle PG, Hunter MJ, Hahn B, Chazin WJ.
J Infect Dis. 2000 Oct;182(4):1272-5. Epub 2000 Sep 5.
PMID 10979933
 
Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.
Srikrishna G, Freeze HH.
Neoplasia. 2009 Jul;11(7):615-28. (REVIEW)
PMID 19568407
 
Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin.
Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK.
Lancet. 1990 Sep 29;336(8718):763-5.
PMID 1976144
 
Up-regulation of the expression of S100A8 and S100A9 in lung adenocarcinoma and its correlation with inflammation and other clinical features.
Su YJ, Xu F, Yu JP, Yue DS, Ren XB, Wang CL.
Chin Med J (Engl). 2010 Aug;123(16):2215-20.
PMID 20819668
 
The dimerization interface of the metastasis-associated protein S100A4 (Mts1): in vivo and in vitro studies.
Tarabykina S, Scott DJ, Herzyk P, Hill TJ, Tame JR, Kriajevska M, Lafitte D, Derrick PJ, Dodson GG, Maitland NJ, Lukanidin EM, Bronstein IB.
J Biol Chem. 2001 Jun 29;276(26):24212-22. Epub 2001 Mar 16.
PMID 11278510
 
RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis.
Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, Nguyen M, Olsson A, Nawroth PP, Bierhaus A, Varki N, Kronenberg M, Freeze HH, Srikrishna G.
Carcinogenesis. 2008 Oct;29(10):2035-43. Epub 2008 Aug 9.
PMID 18689872
 
MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes.
Vogl T, Ludwig S, Goebeler M, Strey A, Thorey IS, Reichelt R, Foell D, Gerke V, Manitz MP, Nacken W, Werner S, Sorg C, Roth J.
Blood. 2004 Dec 15;104(13):4260-8. Epub 2004 Aug 26.
PMID 15331440
 
Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock.
Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J.
Nat Med. 2007 Sep;13(9):1042-9. Epub 2007 Sep 2.
PMID 17767165
 
Expression of S100A8/A9 in HaCaT keratinocytes alters the rate of cell proliferation and differentiation.
Voss A, Bode G, Sopalla C, Benedyk M, Varga G, Bohm M, Nacken W, Kerkhoff C.
FEBS Lett. 2011 Jan 21;585(2):440-6. Epub 2010 Dec 28.
PMID 21192933
 
Proinflammatory properties of the human S100 protein S100A12.
Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL.
J Leukoc Biol. 2001 Jun;69(6):986-94.
PMID 11404386
 
Expression of S100 protein family members in the pathogenesis of bladder tumors.
Yao R, Lopez-Beltran A, Maclennan GT, Montironi R, Eble JN, Cheng L.
Anticancer Res. 2007 Sep-Oct;27(5A):3051-8.
PMID 17970044
 
Induction of apoptotic cell death in mouse lymphoma and human leukemia cell lines by a calcium-binding protein complex, calprotectin, derived from inflammatory peritoneal exudate cells.
Yui S, Mikami M, Yamazaki M.
J Leukoc Biol. 1995 Dec;58(6):650-8.
PMID 7499962
 
Implication of extracellular zinc exclusion by recombinant human calprotectin (MRP8 and MRP14) from target cells in its apoptosis-inducing activity.
Yui S, Nakatani Y, Hunter MJ, Chazin WJ, Yamazaki M.
Mediators Inflamm. 2002 Jun;11(3):165-72.
PMID 12137245
 
The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma.
Zhi H, Zhang J, Hu G, Lu J, Wang X, Zhou C, Wu M, Liu Z.
Int J Cancer. 2003 Sep 1;106(3):327-33.
PMID 12845669
 
Molecular mechanisms of S100-target protein interactions.
Zimmer DB, Wright Sadosky P, Weber DJ.
Microsc Res Tech. 2003 Apr 15;60(6):552-9. (REVIEW)
PMID 12645003
 
Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers.
van Dieck J, Fernandez-Fernandez MR, Veprintsev DB, Fersht AR.
J Biol Chem. 2009 May 15;284(20):13804-11. Epub 2009 Mar 18.
PMID 19297317
 

Citation

This paper should be referenced as such :
Kerkhoff, C ; Ghavami, S
S100A9 (S100 calcium binding protein A9)
Atlas Genet Cytogenet Oncol Haematol. 2011;15(9):746-757.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/S100A9ID45569ch1q21.html


External links

Nomenclature
HGNC (Hugo)S100A9   10499
Cards
AtlasS100A9ID45569ch1q21
Entrez_Gene (NCBI)S100A9  6280  S100 calcium binding protein A9
Aliases60B8AG; CAGB; CFAG; CGLB; 
L1AG; LIAG; MAC387; MIF; MRP14; NIF; P14
GeneCards (Weizmann)S100A9
Ensembl hg19 (Hinxton)ENSG00000163220 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000163220 [Gene_View]  chr1:153357854-153361027 [Contig_View]  S100A9 [Vega]
ICGC DataPortalENSG00000163220
TCGA cBioPortalS100A9
AceView (NCBI)S100A9
Genatlas (Paris)S100A9
WikiGenes6280
SOURCE (Princeton)S100A9
Genetics Home Reference (NIH)S100A9
Genomic and cartography
GoldenPath hg38 (UCSC)S100A9  -     chr1:153357854-153361027 +  1q21.3   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)S100A9  -     1q21.3   [Description]    (hg19-Feb_2009)
EnsemblS100A9 - 1q21.3 [CytoView hg19]  S100A9 - 1q21.3 [CytoView hg38]
Mapping of homologs : NCBIS100A9 [Mapview hg19]  S100A9 [Mapview hg38]
OMIM123886   
Gene and transcription
Genbank (Entrez)AF086362 AK311882 BC047681 CR542207 CR542224
RefSeq transcript (Entrez)NM_002965
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)S100A9
Cluster EST : UnigeneHs.112405 [ NCBI ]
CGAP (NCI)Hs.112405
Alternative Splicing GalleryENSG00000163220
Gene ExpressionS100A9 [ NCBI-GEO ]   S100A9 [ EBI - ARRAY_EXPRESS ]   S100A9 [ SEEK ]   S100A9 [ MEM ]
Gene Expression Viewer (FireBrowse)S100A9 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)6280
GTEX Portal (Tissue expression)S100A9
Protein : pattern, domain, 3D structure
UniProt/SwissProtP06702   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP06702  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP06702
Splice isoforms : SwissVarP06702
PhosPhoSitePlusP06702
Domaine pattern : Prosite (Expaxy)EF_HAND_1 (PS00018)    EF_HAND_2 (PS50222)    S100_CABP (PS00303)   
Domains : Interpro (EBI)EF-hand-dom_pair    EF_Hand_1_Ca_BS    EF_hand_dom    S100-A9    S100/CaBP-9k_CS    S100_Ca-bd_sub   
Domain families : Pfam (Sanger)S_100 (PF01023)   
Domain families : Pfam (NCBI)pfam01023   
Domain families : Smart (EMBL)EFh (SM00054)  S_100 (SM01394)  
Conserved Domain (NCBI)S100A9
DMDM Disease mutations6280
Blocks (Seattle)S100A9
PDB (SRS)1IRJ    1XK4    4GGF    4XJK    5I8N   
PDB (PDBSum)1IRJ    1XK4    4GGF    4XJK    5I8N   
PDB (IMB)1IRJ    1XK4    4GGF    4XJK    5I8N   
PDB (RSDB)1IRJ    1XK4    4GGF    4XJK    5I8N   
Structural Biology KnowledgeBase1IRJ    1XK4    4GGF    4XJK    5I8N   
SCOP (Structural Classification of Proteins)1IRJ    1XK4    4GGF    4XJK    5I8N   
CATH (Classification of proteins structures)1IRJ    1XK4    4GGF    4XJK    5I8N   
SuperfamilyP06702
Human Protein AtlasENSG00000163220
Peptide AtlasP06702
HPRD00472
IPIIPI00027462   
Protein Interaction databases
DIP (DOE-UCLA)P06702
IntAct (EBI)P06702
FunCoupENSG00000163220
BioGRIDS100A9
STRING (EMBL)S100A9
ZODIACS100A9
Ontologies - Pathways
QuickGOP06702
Ontology : AmiGOcytokine production  toll-like receptor signaling pathway  leukocyte migration involved in inflammatory response  positive regulation of peptide secretion  signal transducer activity  calcium ion binding  protein binding  extracellular region  extracellular space  nucleus  nucleoplasm  cytosol  cytosol  cytoskeleton  plasma membrane  regulation of translation  autophagy  apoptotic process  activation of cysteine-type endopeptidase activity involved in apoptotic process  inflammatory response  cell-cell signaling  microtubule binding  zinc ion binding  astrocyte development  antioxidant activity  antimicrobial humoral response  cell junction  positive regulation of blood coagulation  positive regulation of cell growth  neutrophil chemotaxis  extracellular matrix  actin cytoskeleton reorganization  sequestering of zinc ion  chemokine production  secretory granule lumen  peptidyl-cysteine S-trans-nitrosylation  Toll-like receptor 4 binding  defense response to bacterium  neutrophil degranulation  innate immune response  regulation of integrin biosynthetic process  arachidonic acid binding  positive regulation of inflammatory response  RAGE receptor binding  defense response to fungus  positive regulation of NF-kappaB transcription factor activity  regulation of cytoskeleton organization  extracellular exosome  neutrophil aggregation  cellular oxidant detoxification  positive regulation of intrinsic apoptotic signaling pathway  
Ontology : EGO-EBIcytokine production  toll-like receptor signaling pathway  leukocyte migration involved in inflammatory response  positive regulation of peptide secretion  signal transducer activity  calcium ion binding  protein binding  extracellular region  extracellular space  nucleus  nucleoplasm  cytosol  cytosol  cytoskeleton  plasma membrane  regulation of translation  autophagy  apoptotic process  activation of cysteine-type endopeptidase activity involved in apoptotic process  inflammatory response  cell-cell signaling  microtubule binding  zinc ion binding  astrocyte development  antioxidant activity  antimicrobial humoral response  cell junction  positive regulation of blood coagulation  positive regulation of cell growth  neutrophil chemotaxis  extracellular matrix  actin cytoskeleton reorganization  sequestering of zinc ion  chemokine production  secretory granule lumen  peptidyl-cysteine S-trans-nitrosylation  Toll-like receptor 4 binding  defense response to bacterium  neutrophil degranulation  innate immune response  regulation of integrin biosynthetic process  arachidonic acid binding  positive regulation of inflammatory response  RAGE receptor binding  defense response to fungus  positive regulation of NF-kappaB transcription factor activity  regulation of cytoskeleton organization  extracellular exosome  neutrophil aggregation  cellular oxidant detoxification  positive regulation of intrinsic apoptotic signaling pathway  
REACTOMEP06702 [protein]
REACTOME PathwaysR-HSA-6799990 [pathway]   
NDEx NetworkS100A9
Atlas of Cancer Signalling NetworkS100A9
Wikipedia pathwaysS100A9
Orthology - Evolution
OrthoDB6280
GeneTree (enSembl)ENSG00000163220
Phylogenetic Trees/Animal Genes : TreeFamS100A9
HOVERGENP06702
HOGENOMP06702
Homologs : HomoloGeneS100A9
Homology/Alignments : Family Browser (UCSC)S100A9
Gene fusions - Rearrangements
Fusion : MitelmanR3HDM4/S100A9 [19p13.3/1q21.3]  [t(1;19)(q21;p13)]  
Fusion: TCGAC19orf22 S100A9 1q21.3 HNSC
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerS100A9 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)S100A9
dbVarS100A9
ClinVarS100A9
1000_GenomesS100A9 
Exome Variant ServerS100A9
ExAC (Exome Aggregation Consortium)S100A9 (select the gene name)
Genetic variants : HAPMAP6280
Genomic Variants (DGV)S100A9 [DGVbeta]
DECIPHERS100A9 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisS100A9 
Mutations
ICGC Data PortalS100A9 
TCGA Data PortalS100A9 
Broad Tumor PortalS100A9
OASIS PortalS100A9 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICS100A9  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDS100A9
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch S100A9
DgiDB (Drug Gene Interaction Database)S100A9
DoCM (Curated mutations)S100A9 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)S100A9 (select a term)
intoGenS100A9
NCG5 (London)S100A9
Cancer3DS100A9(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM123886   
Orphanet
MedgenS100A9
Genetic Testing Registry S100A9
NextProtP06702 [Medical]
TSGene6280
GENETestsS100A9
Target ValidationS100A9
Huge Navigator S100A9 [HugePedia]
snp3D : Map Gene to Disease6280
BioCentury BCIQS100A9
ClinGenS100A9
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD6280
Chemical/Pharm GKB GenePA34911
Clinical trialS100A9
Miscellaneous
canSAR (ICR)S100A9 (select the gene name)
Probes
Litterature
PubMed353 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineS100A9
EVEXS100A9
GoPubMedS100A9
iHOPS100A9
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Jun 7 12:14:03 CEST 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.